share_log

Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

江蘇恒瑞醫藥股份有限公司(SHSE: 600276)剛剛公佈了第一季度業績:分析師對該股改變主意了嗎?
Simply Wall St ·  04/21 09:40

Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) shareholders are probably feeling a little disappointed, since its shares fell 5.5% to CN¥41.68 in the week after its latest quarterly results. The result was positive overall - although revenues of CN¥6.0b were in line with what the analysts predicted, Jiangsu Hengrui Medicine surprised by delivering a statutory profit of CN¥0.21 per share, modestly greater than expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Jiangsu Hengrui Medicine after the latest results.

江蘇恒瑞醫藥股份有限公司(SHSE: 600276)的股東可能會感到有些失望,因爲其股價在最新季度業績公佈後的一週內下跌了5.5%,至41.68元人民幣。總體業績是積極的——儘管60億元人民幣的收入與分析師的預測一致,但江蘇恒瑞醫藥出人意料地實現了每股0.21元人民幣的法定利潤,略高於預期。對於投資者來說,這是一個重要時刻,因爲他們可以在報告中追蹤公司的業績,看看專家對明年的預測,看看對該業務的預期是否有任何變化。讀者會很高興得知我們已經彙總了最新的法定預測,以了解分析師在最新業績公佈後是否改變了對江蘇恒瑞醫藥的看法。

earnings-and-revenue-growth
SHSE:600276 Earnings and Revenue Growth April 21st 2024
SHSE: 600276 2024 年 4 月 21 日的收益和收入增長

After the latest results, the 22 analysts covering Jiangsu Hengrui Medicine are now predicting revenues of CN¥26.5b in 2024. If met, this would reflect a notable 14% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to soar 25% to CN¥0.87. In the lead-up to this report, the analysts had been modelling revenues of CN¥27.0b and earnings per share (EPS) of CN¥0.89 in 2024. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

在最新業績公佈後,涵蓋江蘇恒瑞醫藥的22位分析師現在預測2024年的收入爲265億元人民幣。如果得到滿足,這將反映出收入與過去12個月相比顯著增長了14%。預計每股法定收益將飆升25%,至0.87元人民幣。在本報告發布之前,分析師一直在模擬2024年的收入爲270億元人民幣,每股收益(EPS)爲0.89元人民幣。鑑於他們的估計沒有重大變化,共識分析師似乎沒有在這些結果中看到任何會改變他們對業務看法的內容。

It will come as no surprise then, to learn that the consensus price target is largely unchanged at CN¥57.89. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Jiangsu Hengrui Medicine analyst has a price target of CN¥120 per share, while the most pessimistic values it at CN¥40.10. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.

因此,得知共識目標股價基本維持在57.89元人民幣也就不足爲奇了。共識目標股價只是個別分析師目標的平均值,因此——可以很方便地看到基礎估計值的範圍有多廣。最樂觀的江蘇恒瑞醫藥分析師將目標股價定爲每股120元人民幣,而最悲觀的分析師則將其估值爲40.10元人民幣。在這種情況下,我們可能會減少對分析師預測的估值,因爲如此廣泛的估計可能意味着該業務的未來難以準確估值。考慮到這一點,我們不會過分依賴共識目標股價,因爲它只是一個平均水平,分析師對該業務的看法顯然存在嚴重分歧。

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. One thing stands out from these estimates, which is that Jiangsu Hengrui Medicine is forecast to grow faster in the future than it has in the past, with revenues expected to display 19% annualised growth until the end of 2024. If achieved, this would be a much better result than the 0.08% annual decline over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 14% annually. Not only are Jiangsu Hengrui Medicine's revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.

我們可以從大局的角度看待這些估計值的另一種方式,例如預測如何與過去的表現相提並論,以及預測相對於業內其他公司是否或多或少看漲。從這些估計中脫穎而出的一點是,預計江蘇恒瑞醫藥未來的增長將比過去更快,預計到2024年底,收入將實現19%的年化增長。如果實現,這將比過去五年0.08%的年下降幅度好得多。相比之下,分析師對整個行業的估計表明,(總計)行業收入預計每年將增長14%。江蘇恒瑞醫藥的收入不僅有望改善,而且分析師似乎也預計其增長速度將超過整個行業。

The Bottom Line

底線

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at CN¥57.89, with the latest estimates not enough to have an impact on their price targets.

最明顯的結論是,該業務的前景最近沒有重大變化,分析師的收益預測保持穩定,與先前的估計一致。幸運的是,他們還再次確認了收入數字,表明收入符合預期。此外,我們的數據表明,收入的增長速度預計將快於整個行業。共識目標股價穩定在57.89元人民幣,最新估計不足以對其目標股價產生影響。

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Jiangsu Hengrui Medicine going out to 2026, and you can see them free on our platform here..

根據這種思路,我們認爲該業務的長期前景比明年的收益重要得多。在Simply Wall St,我們有分析師對江蘇恒瑞醫藥到2026年的全方位估計,你可以在我們的平台上免費看到這些估計。

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

需要考慮的另一件事是管理層和董事最近是否在買入或賣出股票。我們在此處概述了過去十二個月在我們的平台上所有公開市場股票交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論